Inactive Instrument

Actelion Ltd Stock Swiss Exchange

Stocks

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-

31/07/17	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
19/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE

31/07/17	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
19/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
19/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
10/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
10/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/05/17	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/05/17	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/04/17	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/04/17	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/04/17	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/03/17	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
23/02/17	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/04/20	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/06/17	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/06/17	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
16/06/17	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/01/18	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/01/18	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/01/18	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/10/17	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	-2.14%	+3.51%	+74.50%	+131.10%	59.1B
WUXI APPTEC CO., LTD.	-0.93%	+4.05%	+73.64%	+90.53%	55.19B
BIONTECH SE	-2.40%	+1.14%	-13.38%	-9.86%	24.67B
INSMED INCORPORATED	-1.02%	+5.38%	+13.85%	+445.63%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	+0.64%	+14.41%	+44.27%	-3.20%	19.69B
GENMAB A/S	-2.19%	+6.34%	+39.72%	-29.60%	17.56B
PHARMAESSENTIA CORPORATION	+3.58%	+25.11%	+196.41%	+363.46%	16.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+4.91%	+25.24%	+44.61%	-	14.84B
EXELIXIS, INC.	-0.64%	+2.16%	+25.58%	+186.89%	14.04B
Average	-0.00%	+8.39%	+55.47%	+146.87%	27.28B
Weighted average by Cap.	-0.66%	+6.43%	+58.04%	+135.34%